BAUSCH + LOMB CORP

BAUSCH + LOMB CORP

Share · CA0717051076 · BLCO (XTSE)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of BAUSCH + LOMB CORP
Analyst Grade Summary
gauge-img
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell
0
5
8
1
0
No Price
Closing Price XTSE 28.04.2026: 21,58 CAD
28.04.2026 20:00
Current Prices from BAUSCH + LOMB CORP
ExchangeTickerCurrencyLast TradePriceDaily Change
XNYS: NYSE
NYSE
BLCO
USD
28.04.2026 20:00
15,72 USD
-0,16 USD
-1,01 %
IEXG: IEX
IEX
BLCO
USD
28.04.2026 19:59
15,74 USD
-0,15 USD
-0,91 %
XTSE: TSX
TSX
BLCO.TO
CAD
28.04.2026 19:57
21,58 CAD
-0,07 CAD
-0,32 %
XDQU: Quotrix
Quotrix
BLCRSN76.DUSD
EUR
28.04.2026 05:27
13,60 EUR
-
XDUS: Düsseldorf
Düsseldorf
BLCRSN76.DUSB
EUR
27.04.2026 17:32
13,50 EUR
-
Share Float & Liquidity
Free Float 10,54 %
Shares Float 37,56 M
Shares Outstanding 356,38 M
Company Profile for BAUSCH + LOMB CORP Share
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Company Data

Name BAUSCH + LOMB CORP
Company Bausch + Lomb Corporation
Symbol BLCO
Website https://www.bausch.com
Primary Exchange XTSE TSX
ISIN CA0717051076
Asset Class Share
Sector Healthcare
Industry Medical - Instruments & Supplies
CEO Brenton L. Saunders
Market Capitalization 8 Mrd.
Country Canada
Currency CAD
Employees 13,5 T
Address 520 Applewood Crescent, L4K 4B4 Vaughan
IPO Date 2022-05-06

Ticker Symbols

Name Symbol
Düsseldorf BLCRSN76.DUSB
Frankfurt S2L.F
NYSE BLCO
Quotrix BLCRSN76.DUSD
TSX BLCO.TO
More Shares
Investors who hold BAUSCH + LOMB CORP also have the following shares in their portfolio:
DNB BOLIGKRED. 17/27 MTN
DNB BOLIGKRED. 17/27 MTN Bond
Jinan High-tech Development Co., Ltd.
Jinan High-tech Development Co., Ltd. Share